Fragment‐based Identification of Hsp90 Inhibitors
John J. Barker, Oliver Barker, Roberto Boggio et al. · ChemMedChem · 2009
Heat shock protein 90 (Hsp90) plays a key role in stress response and protection of the cell against the effects of mutation. Herein we report the identification of an Hsp90 inhibitor identified by fragment screening using a high-concentration biochemical assay, as well as its optimisation by in silico searching coupled with a structure-based drug design (SBDD) approach.
Cited by 48 works. doi:10.1002/cmdc.200900011
Authors
- John J. Barker
- Oliver Barker
- Roberto Boggio
- Viddhata Chauhan
- Vincent Corden
- Stephen M. Courtney
- Virginie M. Falque
- Fulvia Fusar
- Mihaly Gardiner
- Estelle M.-N. Hamelin
- Thomas Hesterkamp
- Osamu Ichihara
- Owen C. Mather
- Ciro Mercurio
- Saverio Minucci
- Christian Montalbetti
- Annett Müller
References
- Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation
- A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
- The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin
- Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies
- The Heat Shock Protein 90 Antagonist Novobiocin Interacts with a Previously Unrecognized ATP-binding Domain in the Carboxyl Terminus of the Chaperone
- Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer
- Structural and Functional Analysis of the Middle Segment of Hsp90: Implications for ATP Hydrolysis and Client Protein and Cochaperone Interactions
- NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis
- 4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer
- Structure, function, and mechanism of the Hsp90 molecular chaperone